Author:
Shao Yongfu,Lin Yifan,Fang Ziyi,Yan Jianing,Zheng Tuo,Ye Guoliang
Abstract
AbstractHelicobacter pylori (H. pylori) resistance is the most important risk factor for eradication failure. However, in most regions, antibiotic resistance rates of H. pylori in patients with different types of gastric mucosal lesions are still unclear. An 8-year clinical retrospective cohort study involving 2847 patients was performed. In this study, we first summarized and compared the resistance status of H. pylori in different years, ages, sexes, and gastric diseases. The resistance profiles of amoxicillin (AMX), clarithromycin (CLR), levofloxacin (LVX) and furazolidone (FR) and their changing trends in the clinic were described. Then, multiple antibiotic resistance in different gastric diseases and years were described and compared. The relationship between proton pump inhibitor (PPI) medication history and antibiotic resistance in H. pylori was also explored. Finally, an antibiotic resistance risk model was constructed for clinical resistance risk prediction. The overall resistance rates of AMX, CLR, LVX and FR in gastric diseases were 8.18%, 38.11%, 43.98%, and 13.73%, respectively. The mono resistance, double resistance, triple resistance, and quadruple resistance rates were 30.17%, 25.96%, 6.46%, and 0.63%, respectively. Compared with the period from 2014 to 2016, the rates of mono-resistance and multiple resistance all showed relatively downward trends in the past 5 years. Factors including age, sex, type of gastric lesions and recent PPI treatment history are associated with the antibiotic resistance rate of H. pylori. Atrophic gastritis is an important clinical feature of high-risk antibiotic resistance in H. pylori-infected patients. Patients with atrophic gastritis have higher risk of resistant strains infection. In this study, our data provide the association between antibiotic resistance of H. pylori and gastritis pattern, which indicate the higher risk of resistant strain infection if the patients with atrophic gastritis, PPI history and older age.
Funder
Youth Medical Backbone Talents Training Program of Ningbo
National Natural Science Foundation of China
Key Scientific and Technological Projects of Ningbo
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Yang, H. & Hu, B. Diagnosis of Helicobacter pylori infection and recent advances. Diagn. Basel 11, 1305 (2021).
2. Yang, H. & Hu, B. Immunological perspective: Helicobacter pylori infection and gastritis. Med. Inflamm. 8, 2944156 (2022).
3. Deng, L. et al. An improved quantitative real-time polymerase chain reaction technology for Helicobacter pylori detection in stomach tissue and its application value in clinical precision testing. BMC Biotechnol. 20, 33 (2020).
4. Dabbebi, H. et al. Effect of Helicobacter pylori eradication therapy on the response of MALT-Gastric lymphoma. Tunis Med. 100, 37–43 (2022).
5. Rupp, S. et al. Diagnostic approach to Helicobacter pylori-related gastric oncogenesis. Ann. Gastroenterol. 35, 333–344 (2022).